A phase 2/3 trial of Ideaya Biosciences and Servier’s eye cancer candidate has hit its primary endpoint, teeing up a filing for accelerated FDA approval in the second half of the year.
Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula
A phase 2/3 trial of Ideaya Biosciences and Servier’s eye cancer candidate has hit its primary endpoint, teeing up a filing for accelerated FDA approval in the second half of the year.